Progressive Corporation
PGR
$218.49
+2.22%
Progressive Corporation is the largest publicly traded U.S. personal auto insurer by premium volume, underwriting private and commercial auto coverage plus specialty and homeowners lines through a dual distribution model spanning independent agents and direct-to-consumer channels, with roughly 27 million personal auto policies in force. Its competitive identity rests on a data-driven, direct-writing underwriting machine and the 'Snapshot' telematics program, which have consistently delivered combined ratios below the industry and enabled share gains from peers. The current investor debate centers on whether the multi-year margin expansion cycle has peaked: after a period of aggressive rate increases that drove underwriting profitability to exceptional levels, the narrative has shifted toward premium growth deceleration, rate adequacy, and the growing contribution of investment income on a roughly $94 billion float as rates stay elevated. Recent coverage frames Progressive as a high-quality compounder whose underwriting engine is 'still working' but whose headline growth and dividend reliability are being questioned, leaving the stock in a holding pattern as the market digests whether the hard-market tailwind is fading.…
PGR
Progressive Corporation
$218.49
Related headlines
Investment Opinion: Should I buy PGR Today?
Rating: Hold. Progressive is a high-quality compounder with a 37.29% ROE and an 11.9% FCF yield, but the stock lacks a near-term catalyst as revenue growth decelerates to 7.37% and the market questions peak underwriting margins. The analyst consensus is 'hold' with a mean rating of 2.58 and an average target of $230.38, implying only +5.4% upside from $218.49.
Supporting evidence: (1) Valuation is undemanding at 11.81x trailing PE and 13.45x forward PE, well below the 16-21x range seen in 2024-2025; (2) profitability remains robust with a 14.02% net margin and 16.23% operating margin; (3) free cash flow of $15.951 billion supports buybacks and dividends; (4) the 2.15% dividend yield with a 25.4% payout ratio is sustainable. However, revenue growth of 7.37% is the slowest in recent quarters, and the forward PE above trailing PE signals expected earnings decline.
Risks and conditions: The biggest risks are a faster-than-expected margin compression, a forced rate cut to defend market share, and a decline in investment income if rates fall. This Hold would upgrade to Buy if the PE compresses below 10x or if revenue growth re-accelerates above 10% with stable margins. It would downgrade to Sell if underwriting margins fall below 10% net margin or if the stock breaks below the 52-week low of $189.20. Relative to history and peers, the stock is fairly valued to slightly undervalued on earnings, but the premium on book value (4.40x) limits upside until margin visibility improves.
Sign up to view all
PGR 12-Month Price Forecast
Progressive is a high-quality insurer undergoing a transition from peak underwriting margins to a more normalized earnings environment. The stock's 11.81x trailing PE and 4.40x price-to-book are near historical lows, suggesting much of the margin normalization is priced in. However, the lack of a near-term catalyst—revenue growth is decelerating and the forward PE gap signals caution—keeps us neutral. We would upgrade to bullish if Q3 earnings show margin stability and revenue re-acceleration, or if the stock breaks above $239.38 on strong volume. We would downgrade to bearish if margins compress faster than expected or if the stock breaks below $189.20.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Progressive Corporation's 12-month outlook, with a consensus price target around $230.38 and implied upside of +5.4% versus the current price.
Average Target
$230.38
0 analysts
Implied Upside
+5.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$196 - $266
Analyst target range
Coverage is broad with 21 analysts, but sentiment is cautious: the consensus recommendation is 'hold' with a mean rating of 2.58, and the average target price of $230.38 implies roughly +5.4% upside from the current $218.49. The distribution skews neutral-to-negative, with recent actions including Wells Fargo maintaining Underweight, Morgan Stanley upgrading to Equal Weight from Underweight, and KBW upgrading to Outperform from Market Perform — a mixed but slightly improving tone. The consensus leans neutral rather than bullish, reflecting the debate over peak underwriting margins.
The target range of $196.00 to $266.00 is wide, spanning about -10.3% downside to +21.7% upside, which signals meaningful uncertainty about the earnings trajectory. The high target of $266 likely assumes margin resilience, continued investment-income growth on the float, and multiple expansion back toward historical norms, while the low target of $196 prices in margin compression and premium growth stalling. The estimated EPS average of $16.02 (range $13.76-$17.00) against the forward PE of 13.45x implies the market is already discounting some earnings decline, and the wide spread means position sizing should account for binary outcomes around the next rate cycle.
Bulls vs Bears: PGR Investment Factors
The bear case currently has stronger evidence: revenue growth has decelerated to 7.37%, the forward PE exceeds the trailing PE (signaling expected earnings decline), and the stock has underperformed the S&P 500 by 16.99 percentage points over the past year. However, the bull case is not without merit—Progressive's 37.29% ROE, 11.9% FCF yield, and discounted valuation (11.81x PE vs. historical 16-21x) provide a margin of safety. The single most important tension is whether underwriting margins can hold near cycle highs as rate increases moderate; if they do, the stock is cheap, but if they compress meaningfully, the forward PE gap will prove justified. The market is essentially pricing a peak-earnings scenario, leaving room for positive surprise if investment income and disciplined underwriting offset premium deceleration.
Bullish
- Exceptional ROE and low leverage: Progressive generates a 37.29% ROE with a debt-to-equity of only 0.227, a combination that few large financials can match. This capital efficiency supports both buybacks ($614 million in Q2 2026) and a sustainable 25.4% payout ratio on a 2.15% dividend yield.
- Cash generation and FCF yield: Trailing free cash flow of $15.951 billion against a $133.5 billion market cap implies an FCF yield of roughly 11.9%. This cash flow funds growth internally and provides a cushion against underwriting volatility.
- Valuation discount to history: The trailing PE of 11.81x sits well below the 16.15x seen in Q1 2025 and 21.03x in Q2 2024, and the price-to-book of 4.40x is near the low end of its recent 4.1x-5.7x range. This suggests the market has already priced in significant margin normalization.
- Investment income tailwind from $94B float: Progressive's roughly $94 billion float benefits from elevated interest rates, adding a growing earnings stream that is less correlated with underwriting cycles. Recent coverage highlights this as 'the rest of the story' beyond underwriting.
Bearish
- Revenue growth decelerating sharply: Q2 2026 revenue grew 7.37% YoY to $23.617 billion, down from the roughly 12-13% pace of prior-year quarters. The sequential cadence is flattening, and the personal auto book ($18.66 billion) is the swing factor as rate increases moderate.
- Forward PE above trailing signals earnings decline: The forward PE of 13.45x is higher than the trailing PE of 11.81x, an unusual inversion that implies the market expects earnings to fall from the current cycle peak. This is consistent with the view that underwriting margins have peaked.
- Underwriting margin volatility: Quarterly gross margin swung from 37.66% in Q1 2026 to 25.15% in Q2 2026, reflecting timing of underwriting and investment income. This volatility makes earnings less predictable and complicates the margin durability story.
- Significant underperformance vs. market: The 1-year price change of -1.47% contrasts with the S&P 500's +15.53%, a relative strength gap of -16.99 percentage points. The stock is range-bound and lacks directional conviction, with 1-month relative strength of -0.53 versus SPY.
PGR Technical Analysis
Progressive is in a range-bound consolidation phase rather than a clean trend, with the 1-year price change of -1.47% contrasting sharply with the S&P 500's +15.53% over the same period, a relative strength gap of -16.99 percentage points. At the current price of $218.49, the stock sits at roughly 58% of its 52-week range (low $189.20 to high $239.38), meaning it is in the upper-middle of the band but still about 8.7% below the high — a positioning that reflects stalled momentum rather than either overextension or a falling knife. The 6-month gain of +7.85% and YTD gain of +3.00% confirm the stock has recovered from its lows but has not re-established leadership.
Short-term momentum is modestly positive but decelerating: the 1-month change of +0.69% and 3-month change of +5.07% show the stock grinding higher, yet the 1-month relative strength of -0.53 versus SPY's +1.22% indicates it is lagging the market on the margin. The 3-month relative strength of +2.38 is the one bright spot, suggesting a modest outperformance window in the summer, but the 1-year relative strength of -16.99 confirms the longer-term trend remains one of underperformance. The recent price action — a spike to $222.88 on 2026-10-13 followed by a pullback to $213.46 and a rebound to $218.49 — shows choppy, two-way trading consistent with a stock lacking directional conviction; the +2.22% single-day move on the latest print adds to the noise.
Key technical levels are well defined: support sits at the 52-week low of $189.20, roughly 13.4% below the current price, while resistance is the 52-week high of $239.38, about 9.6% above. A breakout above $239.38 would signal a resumption of the longer-term uptrend and likely require a fundamental catalyst such as a better-than-feared rate cycle or strong investment income, whereas a breakdown below $189.20 would confirm the downtrend and open deeper downside. The beta of 0.235 is unusually low — roughly 76% less volatile than the market — which for position sizing means the stock behaves defensively and requires larger notional exposure to achieve a given risk budget, though the max drawdown of -23.47% shows it is not immune to sharp corrections.
Beta
0.23
0.23x market volatility
Max Drawdown
-22.9%
Largest decline past year
52-Week Range
$189-$239
Price range past year
Annual Return
-1.5%
Cumulative gain past year
| Period | PGR Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | +0.2% |
| 3m | +5.1% | +2.9% |
| 6m | +7.9% | +8.4% |
| 1y | -1.5% | +14.9% |
| ytd | +3.0% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PGR Fundamental Analysis
Revenue growth remains solid but is decelerating from the exceptional pace of the hard market: Q2 2026 revenue of $23.617 billion grew 7.37% year-over-year versus $21.995 billion in Q2 2025, a marked slowdown from the roughly 12-13% growth seen in prior-year quarters. The multi-quarter trend shows revenue rising from $20.402 billion in Q1 2025 to $23.617 billion in Q2 2026, but the sequential cadence is flattening, and the segment mix — $18.66 billion Personal Lines versus $2.603 billion Commercial Lines — means the personal auto book is the swing factor. The growth trend implies the investment case is shifting from premium-driven expansion to earnings quality and capital return, which is why the stock has de-rated despite still-strong absolute results.
Profitability is robust and has been expanding: Q2 2026 net income of $3.311 billion on a net margin of 14.02% compares favorably to Q2 2025's $3.175 billion and 14.44% margin, while the trailing net margin of 12.90% and operating margin of 16.23% reflect a business earning well above typical P&C insurance economics. Gross margin of 29.47% (trailing) and 25.15% in Q2 2026 is healthy for an insurer, though the quarterly gross margin has been volatile (37.66% in Q1 2026 versus 25.15% in Q2), reflecting underwriting and investment-income timing. The key takeaway is that Progressive is solidly profitable with margins near cycle highs, but the market is questioning durability as rate increases moderate.
Balance sheet and cash generation are strong: debt-to-equity of 0.227 is conservative, ROE of 37.29% is exceptional, and trailing free cash flow of $15.951 billion against a $133.5 billion market cap implies an FCF yield of roughly 11.9%, underscoring the cash-generative nature of the underwriting model. The current ratio of 0.586 looks low but is typical for insurers whose liabilities are reserves rather than near-term payables, and the interest coverage implied by the low leverage is comfortable. The company funds growth internally and returns capital via buybacks ($614 million in Q2 2026) and dividends, with a payout ratio of 25.4% and dividend yield of 2.15%, so financial risk is low and the balance sheet is not a constraint on the investment case.
Quarterly Revenue
$23.6B
2026-06
Revenue YoY Growth
+7.4%
YoY Comparison
Gross Margin
25.1%
Latest Quarter
Free Cash Flow
$16.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PGR Overvalued?
Because net income is positive ($3.311 billion in Q2 2026), the PE ratio is the primary metric: the trailing PE of 11.81x versus a forward PE of 13.45x is unusual in that the forward multiple is higher than the trailing, implying the market expects earnings to decline from the current cycle peak — consistent with the view that underwriting margins have peaked. The PEG ratio of 0.352 and PS ratio of 1.52 suggest the stock is not expensive on growth-adjusted or sales-based measures, but the forward PE gap is the more telling signal about expected earnings normalization.
Against the P&C insurance sector, a trailing PE of 11.81x and price-to-book of 4.40x present a mixed picture: the earnings multiple is below the sector's typical mid-teens range, suggesting a discount, while the book multiple is elevated, reflecting Progressive's superior ROE of 37.29% versus peers. The EV/EBITDA of 9.47x and EV/Sales of 1.42x are reasonable for a high-quality insurer, and the 2.15% dividend yield with a 25.4% payout ratio is sustainable. The premium on book value is justified by the outsized returns, but the earnings discount signals the market is pricing in mean reversion in underwriting profitability.
Historically, Progressive's PE has ranged from the high single digits to over 20x during weak underwriting periods; the current 11.81x sits in the lower-middle of that band, well below the 16.15x seen in Q1 2025 and the 21.03x in Q2 2024, but above the 8.48x trough in Q2 2026. The price-to-book of 4.40x is near the low end of its recent 4.1x-5.7x range, suggesting the stock is closer to historical value territory than to optimistic pricing — a setup that offers downside protection but requires a catalyst (rate stabilization or investment-income growth) to re-rate higher.
PE
11.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the durability of underwriting margins. Q2 2026 net margin was 14.02%, down slightly from 14.44% in Q2 2025, and quarterly gross margin has been volatile (37.66% in Q1 2026 vs. 25.15% in Q2 2026). Revenue growth of 7.37% YoY is a sharp deceleration from prior-year quarters, and the personal auto segment ($18.66 billion of $23.617 billion) is the key swing factor. A return to adverse loss trends or a need to cut rates to defend market share could compress margins faster than the market expects, especially given the forward PE of 13.45x already discounts some earnings decline. The low current ratio of 0.586 is typical for insurers but warrants monitoring if reserve adequacy deteriorates.
Market and competitive risks include valuation compression if the stock re-rates toward its historical trough multiples. The price-to-book of 4.40x is near the low end of its 4.1x-5.7x range, but a further de-rating to 4.1x would imply roughly 7% downside from current levels. The beta of 0.235 is unusually low, meaning the stock is less sensitive to broad market moves, but it also means it may lag in a strong bull market—as evidenced by the 16.99 percentage point underperformance versus the S&P 500 over the past year. Competitive pressure from peers like Allstate and GEICO could force rate cuts, and regulatory scrutiny of auto insurance pricing remains a background risk. Recent news highlights the debate over whether the hard-market tailwind is fading, which could trigger sector rotation away from P&C insurers.
Worst-case scenario: a combination of accelerating loss trends, forced rate cuts to retain policies, and a sharp decline in investment income if interest rates fall would compress earnings well below the $16.02 consensus EPS estimate. In that scenario, the stock could retest its 52-week low of $189.20, representing roughly -13.4% downside from the current $218.49. A more severe outcome, such as a regulatory crackdown or a major reserve charge, could push the stock toward the analyst low target of $196 (-10.3%) or below. The max drawdown of -23.47% over the past year shows the stock is capable of sharp corrections, and a repeat would imply a price near $167, though that is not our base case.
FAQ
The key risks are: (1) margin compression—net margin fell to 14.02% in Q2 2026 from 14.44% a year earlier, and gross margin is volatile; (2) revenue deceleration—growth slowed to 7.37% YoY, and further slowdown could pressure the multiple; (3) investment income risk—a decline in interest rates would reduce income on the $94 billion float; (4) competitive and regulatory risks—peers may force rate cuts, and regulators could scrutinize auto insurance pricing. The most severe risk is a sharp margin decline that pushes the stock toward its 52-week low of $189.20.
Our 12-month forecast has three scenarios: bull case (25% probability) targeting $239.38-$266.00 if margins hold and investment income grows; base case (55% probability) targeting $220-$235, in line with the analyst average of $230.38; and bear case (20% probability) targeting $189.20-$196.00 if margin compression accelerates. The base case is most likely, assuming revenue growth stabilizes at 5-8% and net margin holds above 12%. The key assumption is that underwriting margins normalize gradually rather than sharply.
PGR appears fairly valued to slightly undervalued on earnings. The trailing PE of 11.81x is below the sector's mid-teens range and well below its own historical 16-21x in 2024-2025. The price-to-book of 4.40x is near the low end of its recent 4.1x-5.7x range, justified by a 37.29% ROE. However, the forward PE of 13.45x is higher than the trailing, implying the market expects earnings to decline. This suggests the stock is pricing in a peak-earnings scenario, leaving limited upside unless margins prove resilient.
PGR is a good buy for long-term investors who value quality and are willing to tolerate near-term uncertainty. The stock trades at 11.81x trailing earnings, well below its historical range, and offers a 37.29% ROE and an 11.9% FCF yield. However, revenue growth has decelerated to 7.37%, and the analyst consensus is 'hold' with only +5.4% upside to the average target of $230.38. The biggest downside risk is a retest of the 52-week low of $189.20 (-13.4%). For risk-averse investors, waiting for margin stabilization or a better entry point near $200 may be prudent.
PGR is best suited for long-term investment. Its beta of 0.235 makes it a low-volatility defensive holding, but the stock has underperformed the S&P 500 by 16.99 percentage points over the past year, and near-term catalysts are limited. The 2.15% dividend yield and 25.4% payout ratio provide income, while the 37.29% ROE and 11.9% FCF yield support compounding over time. Short-term traders may find the range-bound action (52-week range $189.20-$239.38) unappealing. A minimum holding period of 2-3 years is suggested to ride out the underwriting cycle.